Logo image of CALA

CALITHERA BIOSCIENCES INC (CALA) Stock Fundamental Analysis

NASDAQ:CALA - Nasdaq - US13089P5070 - Common Stock - Currency: USD

0.3651  -0.04 (-10.95%)

After market: 0.3401 -0.02 (-6.85%)

Fundamental Rating

3

Taking everything into account, CALA scores 3 out of 10 in our fundamental rating. CALA was compared to 556 industry peers in the Biotechnology industry. CALA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CALA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CALA has reported negative net income.
CALA had a negative operating cash flow in the past year.
CALA Yearly Net Income VS EBIT VS OCF VS FCFCALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for CALA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CALA Yearly ROA, ROE, ROICCALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -50 -100 -150 -200

1.3 Margins

CALA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALA Yearly Profit, Operating, Gross MarginsCALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -200 -400 -600 -800 -1K

More info and screens

6

2. Health

2.1 Basic Checks

CALA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CALA has been reduced compared to 1 year ago.
CALA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CALA Yearly Shares OutstandingCALA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
CALA Yearly Total Debt VS Total AssetsCALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -27.42, we must say that CALA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -27.42, CALA is doing worse than 91.98% of the companies in the same industry.
CALA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.42
ROIC/WACCN/A
WACC9.19%
CALA Yearly LT Debt VS Equity VS FCFCALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.76 indicates that CALA has no problem at all paying its short term obligations.
CALA's Current ratio of 3.76 is on the low side compared to the rest of the industry. CALA is outperformed by 66.98% of its industry peers.
A Quick Ratio of 3.76 indicates that CALA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.76, CALA is doing worse than 65.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 3.76
CALA Yearly Current Assets VS Current LiabilitesCALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.17% over the past year.
Looking at the last year, CALA shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
Measured over the past years, CALA shows a very negative growth in Revenue. The Revenue has been decreasing by -24.04% on average per year.
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.04%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 14.34% on average over the next years. This is quite good.
The Revenue is expected to grow by 120.38% on average over the next years. This is a very strong growth
EPS Next Y69.34%
EPS Next 2Y38.25%
EPS Next 3Y23.9%
EPS Next 5Y14.34%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CALA Yearly Revenue VS EstimatesCALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2025 2026 2027 200M 400M 600M 800M
CALA Yearly EPS VS EstimatesCALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CALA. In the last year negative earnings were reported.
Also next year CALA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CALA Price Earnings VS Forward Price EarningsCALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALA Per share dataCALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

CALA's earnings are expected to grow with 23.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.25%
EPS Next 3Y23.9%

More info and screens

0

5. Dividend

5.1 Amount

CALA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALITHERA BIOSCIENCES INC

NASDAQ:CALA (2/1/2023, 8:04:28 PM)

After market: 0.3401 -0.02 (-6.85%)

0.3651

-0.04 (-10.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)03-29 2023-03-29/amc
Inst OwnersN/A
Inst Owner Change0%
Ins Owners111.41%
Ins Owner Change0%
Market Cap1.78M
Analysts84
Price Target5.1 (1296.88%)
Short Float %0.41%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.48%
Min EPS beat(2)-2.28%
Max EPS beat(2)41.23%
EPS beat(4)3
Avg EPS beat(4)11.38%
Min EPS beat(4)-2.28%
Max EPS beat(4)41.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.12%
EPS NQ rev (1m)11.13%
EPS NQ rev (3m)11.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-205.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.07
EV/EBITDA N/A
EPS(TTM)-12
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-12.48
FCFYN/A
OCF(TTM)-12.45
OCFYN/A
SpS0
BVpS5.42
TBVpS5.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.43%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 3.76
Altman-Z -27.42
F-Score2
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)23.75%
Cap/Depr(5y)88.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33%
EPS Next Y69.34%
EPS Next 2Y38.25%
EPS Next 3Y23.9%
EPS Next 5Y14.34%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.04%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.38%
EBIT growth 1Y-50.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24%
OCF growth 3YN/A
OCF growth 5YN/A